MEDICAL DEVICE INNOVATION - Medical Device Daily

MEDICAL DEVICE INNOVATION 2010
29
2011, which puts the company in position for a CE mark by
2013, and hopefully on the U.S. market by sometime in 2015.
“It will no doubt be a long project and a capital intensive
project, but we feel good about the fact that others are in
this space on aortic side.”
He added that hopefully by the time CVT applies for
FDA approval, those companies with PAVR technologies
would have already addressed some of the regulatory hurdles
for valve replacement procedures. The $750,000 seed
funding is an important step toward accomplishing those
development goals.
“The move from basic science to clinical evaluation is
especially difficult and expensive,” said David Tancredi,
MD, PhD, scientific director of Fondation Leducq. “Because
funding at the early stage of a med-tech company’s evolution
is particularly difficult to obtain, promising new technology
may simply be abandoned. In CVT’s case, our goal is
to prevent that from happening.”
(This story originally appeared in the May 13, 2009, edition
of Medical Device Daily).
To subscribe, please call MEDICAL DEVICE DAILY Customer Service at (800) 888-3912; outside the U.S. and Canada, call (404) 262-5547.
Copyright © 2010 AHC Media LLC. Reproduction is strictly prohibited.